Part 2 – Applying Lean Principles to Meet Regulatory Expectations
Applying lean principles to documentation and configurations ensures a balanced approach. Continuous evaluation is crucial to confirm that these efforts add value, enhance compliance, and improve quality without introducing waste or unnecessary complexity. Focusing on simplicity, efficiency, and flexibility, lean documentation and configuration aim to enhance product development processes, streamline compliance, and enable more effective responses to changes and innovations.
Regulations
The Quality System Regulation (QSR) 21 CFR Part 820 and ISO 13485, including upcoming regulatory updates, are the key frameworks defining quality management system requirements for the medical device industry, particularly for design control documents.
Quality System Regulation (QSR), 21 CFR Part 820
21 CFR Part 820, the Quality System Regulation (QSR) set by the U.S. FDA, outlines quality system requirements for manufacturing and designing medical devices. Design Controls are mandated by the QSR, and describe the specific documents required to ensure product quality, safety and compliance.
Key aspects of Design Controls under QSR include:
- Design and Development Planning: Requires a documented plan detailing design and development activities, milestones, and responsibilities.
- Design Inputs: Documents user needs, intended use, regulatory requirements, and industry standards.
- Design Outputs: Must align with inputs, including technical drawings, manufacturing instructions, and product specifications.
- Design Reviews: Formal reviews conducted as prescribed by the Design and Development Plan. These sessions are documented with meeting notes, decisions, and follow-up actions.
- Design Verification and Validation: Confirm the design meets requirements and performs as intended, with test protocols, results, and analysis documented.
- Design Changes: Documented review and approval of all changes, with impact assessments and justifications that refer specifically to supportive data and cross-reference all documents that have been changed.
- Design Transfer: Documentation proving proper transfer from development to production.
ISO 13485 is an international standard for quality management systems in the medical device industry, sharing similarities with 21 CFR Part 820 but with a broader global focus. ISO 13485 mandates clear and comprehensive procedures for design and development, from concept to production. Design and Development Inputs must be comprehensively documented, emphasizing regulatory and safety requirements and user needs. Design and Development Outputs, such as technical drawings, manufacturing processes, and product specifications, must be documented to facilitate verification, manufacturing, and service. Design and Development Reviews must be documented with clearly defined stages and cross-functional team participation. Verification and Validation stages must be thoroughly documented, proving compliance with design inputs and user needs. Design and Development Changes must be controlled with documentation detailing rationale, impact assessment, and necessary approvals. Both ISO 13485 and 21 CFR Part 820 require documentation to ensure a smooth transition from design to production, known as design and development transfer.
Both 21 CFR Part 820 and ISO 13485 emphasize documenting design controls to ensure quality, safety, and regulatory compliance. While 21 CFR Part 820 is specific to FDA regulations in the U.S., ISO 13485 is an international standard. Together, they offer a comprehensive framework for managing medical device design and development, maintaining quality and safety throughout the product lifecycle. Recognizing this, FDA issued a final rule in January 2024 to amend the current medical device regulations (21 CFR 820) “to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world.” (Source: Quality Management System Regulation: Final Rule Amending the Quality System Regulation – Frequently Asked Questions, 31 Jan 2024, FDA.gov). This action should prompt medical device manufacturers to more closely examine both quality and operational decisions made throughout the development lifecycle.